Phase 3 ONWARD3 data demonstrate sustained skin clearance, pruritus relief, and quality of life improvements with ...

Experts at the 2026 Fall Clinical Dermatology Conference review landmark drug approvals, emerging pipelines, and updated ...

The Food and Drug Administration (FDA) has approved Weltruza ™ (olanzapine) as the first once-monthly subcutaneous long-acting injectable (LAI) for the treatment of schizophreni ...

Serum ferritin threshold of less than or equal to 20ng/mL is suggested for children ages 9 months to 4 years. HealthDay News — In guidelines issued by the American Society of Hematology and published ...

Officials say low vaccination rates in rural communities are fueling the spread of the highly contagious virus.

The effect of semaglutide on major adverse cardiovascular events (MACE) is only partially due to known risk factors, according to a study published online September 23 in the European Heart Journal.

In national prospective study, 2.9% of those undergoing anesthesia reported receiving GLP-1 receptor agonists.

Key insights from Fall Clinical 2026 on diagnosing and managing inflammatory skin conditions and post-inflammatory dyspigmentation in patients with skin of color.

Phase 3 PROPEL 3 trial results show daily oral infigratinib significantly improved annualized height velocity and height Z-scores compared with placebo in children with achondroplasia.

Juvmo (tavapadon) offers a novel, selective D1/D5 dopamine receptor partial agonist mechanism for early monotherapy and adjunctive treatment in Parkinson disease.

Key takeaways from the 26th annual Fall Clinical Dermatology Conference held in Las Vegas, Nevada were published.

Findings seen among pediatric patients presenting to the emergency department with moderate-to-severe acute pain ...